Merck, Moderna expect to profit from coronavirus vaccines

July 21, 2020

Merck & Co and Moderna have told a U.S. Congressional panel that, once approved, they expect to profit from their coronavirus vaccines.

Merck chief patient officer Julie Gerberding told the House of Representatives subcommittee on oversight and investigations in a virtual, off-site hearing that it has no plans of selling its vaccine at cost. Johnson & Johnson and AstraZeneca have testified that they will price their potential vaccines at no profit.

Moderna and AstraZeneca have received U.S. funding for its vaccine development while Pfizer has not.

Merck’s has yet to begin human studies of its experimental vaccine.

Read the Reuters report